Valuation: Krystal Biotech, Inc.

Market Cap 9.94B 8.58B 8.05B 7.33B 13.78B 950B 13.97B 94.35B 36.97B 476B 37.31B 36.5B 1,583B P/E 2026 *
44.3x
P/E 2027 * 35.8x
Enterprise Value 9.94B 8.58B 8.05B 7.33B 13.78B 950B 13.97B 94.35B 36.97B 476B 37.31B 36.5B 1,583B EV / Sales 2026 *
19.4x
EV / Sales 2027 * 15.2x
Free-Float
89.07%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week+1.25%
Current month-1.58%
1 month-5.39%
3 months+9.61%
6 months+16.64%
Current year+36.18%
1 week 320.62
Extreme 320.62
337.2
1 month 297.02
Extreme 297.02
369
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Executive Officer 61 2016-04-14
Chief Operating Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap.
8/14/26 Don

Director

-28,691 0.0973%
3/1/26 Other

EVP, Head of International

51,478 0.1761%
3/1/26 Other

General Counsel

68,165 0.2332%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+1.25%+123.42%+185.00% 9.94B
+0.30%-0.26%+38.86%+1.15% 80.48B
-1.02%-1.34%-2.54%+30.42% 50.63B
-0.42%-5.17%+9.75%+166.46% 47.57B
+17.25%+14.09%-41.83%-41.67% 45.84B
-0.32%+0.98%+50.90%-20.02% 30.9B
+1.80%+7.77%+130.05%-39.33% 25.73B
+2.78%+1.60%+42.08%+92.34% 25.03B
+1.36%+1.15%-5.15%+207.31% 21.16B
+1.14%+5.03%+64.98%+126.81% 16.75B
Average +1.92%+0.54%+41.05%+70.85% 35.4B
Weighted average by Cap. +2.22%-0.06%+27.47%+47.09%

Financials

2026 *2027 *
Net sales 513M 443M 415M 378M 711M 49.01B 721M 4.87B 1.91B 24.56B 1.92B 1.88B 81.68B 655M 565M 530M 483M 908M 62.58B 921M 6.21B 2.44B 31.35B 2.46B 2.4B 104B
Net income 237M 205M 192M 175M 329M 22.7B 334M 2.25B 883M 11.37B 891M 872M 37.83B 307M 265M 248M 226M 425M 29.31B 431M 2.91B 1.14B 14.69B 1.15B 1.13B 48.85B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-17 US$335.73 +1.04% 255,136
26-08-14 US$332.27 +1.20% 167,864
26-08-13 US$328.34 -1.36% 135,628
26-08-12 US$332.86 +1.78% 161,951
26-08-11 US$327.05 -1.37% 147,901
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
335.73USD
Average target price
385.00USD
Spread / Average Target
+14.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock